IP Library Granted Patent US 8,158,769
Granted Patent B2
US 8,158,769 · App. 12/895,052 · Granted Apr 17, 2012

Members of the capsaicin/vanilloid receptor family of proteins and uses thereof

Assignee: Bayer Schering Pharma Aktiengesellschaft
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,158,769
App. No.
12/895,052
Granted
Apr 17, 2012
Kind
B2
Abstract

The invention provides isolated nucleic acids molecules, designated hVR-1, hVR-2, and rVR-2 nucleic acid molecules, which encode novel members of the Capsaicin/Vanilloid receptor family. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing hVR-1, hVR-2, and rVR-2 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an hVR-1, hVR-2, and rVR-2 gene has been introduced or disrupted. The invention still further provides isolated hVR-1, hVR-2, and rVR-2 proteins, fusion proteins, antigenic peptides and anti-hVR-1, anti-hVR-2, and anti-rVR-2 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

Claims (15)

1. An isolated nucleic acid molecule which encodes a polypeptide selected from the group consisting of

(1) a polypeptide comprising the amino acid sequence set forth in SEQ ID NO:2;

(2) a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:2;

(3) a polypeptide comprising an amino acid sequence at least about 87% identical to the amino acid sequence of SEQ ID NO:2; and

(4) a polypeptide comprising at least 200 contiguous amino acid residues of the amino acid sequence of SEQ ID NO:2.

2. The isolated nucleic acid molecule of claim 1 further comprising a nucleotide sequence encoding a heterologous polypeptide.

3. The isolated nucleic acid molecule of claim 1 which is a vector.

4. The isolated nucleic acid molecule of claim 3 which is an expression vector.

5. The isolated nucleic acid molecule of claim 1 which comprises SEQ ID NO:1.

6. The isolated nucleic acid molecule of claim 3 which comprises SEQ ID NO:1.

7. The isolated nucleic acid molecule of claim 4 which comprises SEQ ID NO:1.

8. A host cell transfected with an expression vector which comprises a nucleic acid molecule which encodes a polypeptide selected from the group consisting of (1) a polypeptide comprising the amino acid sequence set forth in SEQ ID NO:2; (2) a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:2; (3) a polypeptide comprising an amino acid sequence at least about 87% identical to the amino acid sequence of SEQ ID NO:2; and (4) a polypeptide comprising at least 200 contiguous amino acid residues of the amino acid sequence of SEQ ID NO:2.

9. The host cell of claim 8 , wherein the expression vector comprises SEQ ID NO:1.

10. A method, comprising culturing a host cell in an appropriate culture medium, wherein the host cell comprises an expression vector and wherein the expression vector comprises a nucleic acid molecule which encodes a polypeptide selected from the group consisting of (1) a polypeptide comprising the amino acid sequence set forth in SEQ ID NO:2; (2) a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:2; (3) a polypeptide comprising an amino acid sequence at least about 87% identical to the amino acid sequence of SEQ ID NO:2; and (4) a polypeptide comprising at least 200 contiguous amino acid residues of the amino acid sequence of SEQ ID NO:2, thereby expressing the polypeptide encoded by the nucleic acid molecule.

11. The method of claim 10 wherein the nucleic acid molecule comprises SEQ ID NO:1.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 28, 2010
From: CURTIS, RORY A. J.
To: MILLENNIUM PHARMACEUTICALS, INC.
Reel/Frame 025211/0830 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 28, 2010
From: MILLENNIUM PHARMACEUTICALS, INC.
To: BAYER HEALTHCARE AG
Reel/Frame 025212/0210 →
MERGER Recorded Oct 28, 2010
From: BAYER HEALTHCARE AG
To: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
Reel/Frame 025212/0329 →
Continuity (9)
Division 11967558 · Dec 31, 2007
Continuation 11013090 · Dec 15, 2004
Division 09587111 · Jun 2, 2000
Division 09439165 · Nov 12, 1999
Continuation In Part 09421134 · Oct 19, 1999
Continuation In Part 09258633 · Feb 26, 1999
Provisional Application 60114078 · Dec 28, 1998
Provisional Application 60108322 · Nov 13, 1998
Related Publication 20110033892A1 · Feb 10, 2011